BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Milano G, Etienne-Grimaldi MC, Mari M, Lassalle S, Formento JL, Francoual M, Lacour JP, Hofman P. Candidate mechanisms for capecitabine-related hand-foot syndrome. Br J Clin Pharmacol. 2008;66:88-95. [PMID: 18341672 DOI: 10.1111/j.1365-2125.2008.03159.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 68] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Yang B, Xie X, Lv D, Hu J, Chen Y, Wu Z, Luo S, Zhang S. Capecitabine induces hand-foot syndrome through elevated thymidine phosphorylase-mediated locoregional toxicity and GSDME-driven pyroptosis that can be relieved by tipiracil. Br J Cancer 2022. [DOI: 10.1038/s41416-022-02039-3] [Reference Citation Analysis]
2 Yoshida Y, Sasaoka S, Tanaka M, Matsumoto K, Inoue M, Satake R, Shimada K, Mukai R, Suzuki T, Iwata M, Goto F, Mori T, Mori K, Yoshimura T, Nakamura M. Analysis of drug-induced hand–foot syndrome using a spontaneous reporting system database. Therapeutic Advances in Drug Safety 2022;13:204209862211019. [DOI: 10.1177/20420986221101963] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Santhosh A, Kumar A, Pramanik R, Gogia A, Prasad CP, Gupta I, Gupta N, Cheung WY, Pandey RM, Sharma A, Batra A. Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study). Trials 2022;23:420. [PMID: 35590388 DOI: 10.1186/s13063-022-06353-2] [Reference Citation Analysis]
4 Hussain H, Fadel A, Guardiola V, Rodriguez S. A Rare Case of Non-immune Hemolytic Anemia in a Stage IV Breast Cancer Patient Treated With Capecitabine. Cureus 2022. [DOI: 10.7759/cureus.24921] [Reference Citation Analysis]
5 Rodríguez-garzotto A, Iglesias-docampo L, Díaz-garcía CV, Ruppen I, Ximénez-embún P, Gómez C, Rodríguez-peralto JL, de Frutos JO, Lopez-martin JA, Grávalos C, Cortés-funes H, Agulló-ortuño MT. Topical heparin as an effective and safe treatment for patients with capecitabine-induced hand-foot syndrome: results of a phase IIA trial supported by proteomic profiling of skin biopsies. Ther Adv Med Oncol 2022;14:175883592210869. [DOI: 10.1177/17588359221086911] [Reference Citation Analysis]
6 Kalman TI. Rational Design of an Orally Active Anticancer Fluoropyrimidine, Pencitabine, a Hybrid of Capecitabine and Gemcitabine. ACS Med Chem Lett 2022;13:409-16. [PMID: 35300092 DOI: 10.1021/acsmedchemlett.1c00565] [Reference Citation Analysis]
7 Mohajerani R, Shahi F, Jafariazar Z, Afshar M. Efficacy of topical Lawsonia inermis L. (Henna) hydrogel in fluorouracil-induced hand-foot syndrome: a pilot randomized double-blind placebo-controlled clinical trial. Cutan Ocul Toxicol 2021;40:257-62. [PMID: 34152880 DOI: 10.1080/15569527.2021.1940194] [Reference Citation Analysis]
8 Ahn HR, Lee SK, Youn HJ, Yun SK, Lee IJ. Stevens-Johnson syndrome and concurrent hand foot syndrome during treatment with capecitabine: A case report. World J Clin Cases 2021; 9(17): 4279-4284 [PMID: 34141791 DOI: 10.12998/wjcc.v9.i17.4279] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Chen J, Wang Z. How to conduct integrated pharmaceutical care for patients with hand-foot syndrome associated with chemotherapeutic agents and targeted drugs. J Oncol Pharm Pract 2021;27:919-29. [PMID: 33874817 DOI: 10.1177/10781552211009291] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Janssen JM, Jacobs BAW, Roosendaal J, Derissen EJB, Marchetti S, Beijnen JH, Huitema ADR, Dorlo TPC. Population Pharmacokinetics of Intracellular 5-Fluorouridine 5'-Triphosphate and its Relationship with Hand-and-Foot Syndrome in Patients Treated with Capecitabine. AAPS J 2021;23:23. [PMID: 33417061 DOI: 10.1208/s12248-020-00533-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Neumann NR, Hoyte CO. Fluorouracil or Capecitabine Overdose. Oncologic Emergency Medicine 2021. [DOI: 10.1007/978-3-030-67123-5_54] [Reference Citation Analysis]
12 Ni C, Fang J, Qian H, Xu Q, Shen F. Liposomal doxorubicin-related palmar-plantar erythrodysesthesia (hand-foot syndrome): a case report. J Int Med Res 2020;48:300060520974854. [PMID: 33356712 DOI: 10.1177/0300060520974854] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Chauhan P, Gupta A, Kumar S, Bishnu A, Nityanand S. Palmar‐plantar erythrodysesthesia associated with high‐dose methotrexate: Case report. Cancer Reports 2020;3. [DOI: 10.1002/cnr2.1270] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Ruiz-Pinto S, Pita G, Martín M, Nuñez-Torres R, Cuadrado A, Shahbazi MN, Caronia D, Kojic A, Moreno LT, de la Torre-Montero JC, Lozano M, López-Fernández LA, Ribelles N, García-Saenz JA, Alba E, Milne RL, Losada A, Pérez-Moreno M, Benítez J, González-Neira A. Regulatory CDH4 Genetic Variants Associate With Risk to Develop Capecitabine-Induced Hand-Foot Syndrome. Clin Pharmacol Ther 2021;109:462-70. [PMID: 32757270 DOI: 10.1002/cpt.2013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
15 Watanabe K, Ishibe A, Watanabe J, Ota M, Fujii S, Ichikawa Y, Oba MS, Endo I. The effect of TJ-28 (Eppikajutsuto) on the prevention of hand-foot syndrome using Capecitabine for colorectal cancer: The Yokohama Clinical Oncology Group Study (YCOG1102). Indian J Gastroenterol 2020;39:204-10. [DOI: 10.1007/s12664-020-01039-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
16 Ang FLI, Rowland A, Modi ND, McKinnon RA, Sorich MJ, Hopkins AM. Early Adverse Events predict Survival Outcomes in HER2-positive Advanced Breast Cancer Patients treated with Lapatinib plus Capecitabine. J Cancer 2020;11:3327-33. [PMID: 32231738 DOI: 10.7150/jca.41996] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Latifyan S, Genot MT, Fernez B, Scharll MF, Klastersky JA. Use of low-level laser therapy (LLLT) or photobiomodulation (PBM) for the management of the hand-foot syndrome (HSF) or palmo-plantar erythrodysesthesia (PPED) associated with cancer therapy. Support Care Cancer 2020;28:3287-90. [PMID: 31754836 DOI: 10.1007/s00520-019-05099-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Ai L, Xu Z, Yang B, He Q, Luo P. Sorafenib-associated hand-foot skin reaction: practical advice on diagnosis, mechanism, prevention, and management. Expert Rev Clin Pharmacol 2019;12:1121-7. [PMID: 31679411 DOI: 10.1080/17512433.2019.1689122] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
19 Aquilani R, Brugnatelli S, Dossena M, Maestri R, Delfanti S, Buonocore D, Boschi F, Simeti E, Condino AM, Verri M. Oxaliplatin-Fluoropyrimidine Combination (XELOX) Therapy Does Not Affect Plasma Amino Acid Levels and Plasma Markers of Oxidative Stress in Colorectal Cancer Surgery Patients: A Pilot Study. Nutrients 2019;11:E2667. [PMID: 31694176 DOI: 10.3390/nu11112667] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
20 Yaghobi Joybari A, Azadeh P, Ghiasi HA, Amouzegar A, Yaseri M, Amini A, Farasatinasab M, Mokhtari M. Capecitabine induced fingerprint changes. J Clin Pharm Ther 2019;44:780-7. [DOI: 10.1111/jcpt.13003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
21 Kataria PS, Kendre PP, Patel AA, Tahiliani N, Bhargav V, Parekh H. Rare occurrence of hand-foot syndrome due to paclitaxel: A rare case report. Indian J Pharmacol 2018;50:284-6. [PMID: 30636833 DOI: 10.4103/ijp.IJP_547_17] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
22 Jacobs BAW, Pluim D, van der Laan P, Tzani A, Beijnen JH, Schellens JHM. Development and validation of a quantitative method for thymidine phosphorylase activity in peripheral blood mononuclear cells. Nucleosides Nucleotides Nucleic Acids 2018;37:436-54. [PMID: 30285552 DOI: 10.1080/15257770.2018.1498270] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Milano G, Innocenti F, Lacarelle B, Ciccolini J. “No pain, No gain” still true with immunotherapy: When the finger shows the moon, look at the moon! Critical Reviews in Oncology/Hematology 2018;127:1-5. [DOI: 10.1016/j.critrevonc.2018.04.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
24 . Antimetabolites. Anticancer Therapeutics 2017. [DOI: 10.1002/9781118696194.ch2.2] [Reference Citation Analysis]
25 Dar W, Hussain M, Aziz SA, Mohammad G, Wani B, Latief M. Uncommon Adverse Effects of Commonly Used Chemotherapeutic Agents in Medical Oncology Practice: A Series of Two Cases of Hand‑Foot Syndrome. Indian Journal of Medical and Paediatric Oncology 2021;38:380-2. [DOI: 10.4103/ijmpo.ijmpo_70_16] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
26 Roberto M, Romiti A, Botticelli A, Mazzuca F, Lionetto L, Gentile G, Paris I, Falcone R, Bassanelli M, Di Pietro FR, Onesti CE, Anselmi E, Macrini S, Simmaco M, Marchetti P. Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine. Eur J Clin Pharmacol 2017;73:157-64. [DOI: 10.1007/s00228-016-2160-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
27 Lou Y, Wang Q, Zheng J, Hu H, Liu L, Hong D, Zeng S. Possible Pathways of Capecitabine-Induced Hand–Foot Syndrome. Chem Res Toxicol 2016;29:1591-601. [DOI: 10.1021/acs.chemrestox.6b00215] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
28 Lam SW, Guchelaar HJ, Boven E. The role of pharmacogenetics in capecitabine efficacy and toxicity. Cancer Treat Rev. 2016;50:9-22. [PMID: 27569869 DOI: 10.1016/j.ctrv.2016.08.001] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 8.7] [Reference Citation Analysis]
29 Ciccolini J, Serdjebi C, Le Thi Thu H, Lacarelle B, Milano G, Fanciullino R. Nucleoside analogs: ready to enter the era of precision medicine? Expert Opinion on Drug Metabolism & Toxicology 2016;12:865-77. [DOI: 10.1080/17425255.2016.1192128] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
30 Yadav N, Madke B, Kar S, Prasad K. Liposomal doxorubicin-induced palmoplantar erythrodysthesia syndrome. Indian Dermatol Online J 2015;6:366-8. [PMID: 26500878 DOI: 10.4103/2229-5178.164488] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
31 Kruger S, Boeck S, Heinemann V, Laubender RP, Vehling-Kaiser U, Waldschmidt D, Kettner E, Märten A, Winkelmann C, Klein S, Kojouharoff G, Gauler TC, Fischer von Weikersthal L, Clemens MR, Geissler M, Greten TF, Hegewisch-Becker S, Modest DP, Stintzing S, Haas M. Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104. Acta Oncol 2015;54:993-1000. [PMID: 25924969 DOI: 10.3109/0284186X.2015.1034877] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
32 Tognetti L, Fimiani M, Rubegni P. Benign dermoscopic parallel ridge pattern in plantar hyperpigmentation due to capecitabine. Dermatol Pract Concept 2015;5:79-81. [PMID: 26114058 DOI: 10.5826/dpc.0502a14] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
33 Lamberti M, Porto S, Zappavigna S, Stiuso P, Tirino V, Desiderio V, Mele L, Caraglia M. Levofolene modulates apoptosis induced by 5-fluorouracil through autophagy inhibition: clinical and occupational implications. Int J Oncol 2015;46:1893-900. [PMID: 25709090 DOI: 10.3892/ijo.2015.2904] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
34 Fabbrocini G, Panariello L, Caro G, Monfrecola G. Chemotherapy and Cutaneous Drug Reactions. Cutaneous Drug Eruptions 2015. [DOI: 10.1007/978-1-4471-6729-7_29] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
35 Li Z, Jiang N, Xu Y. The concurrence of subacute cutaneous lupus erythematosus and hand-foot syndrome in a patient undergoing capecitabine chemotherapy: SCLE concurrent with HFS. Australasian Journal of Dermatology 2016;57:e14-6. [DOI: 10.1111/ajd.12224] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
36 Meadows KL, Rushing C, Honeycutt W, Latta K, Howard L, Arrowood CA, Niedzwiecki D, Hurwitz HI. Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study. Support Care Cancer 2015;23:1311-9. [PMID: 25341548 DOI: 10.1007/s00520-014-2465-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
37 Palaniappan M, Srinivasamurthy S, Dubashi B, Chandrasekaran A. Anticancer drug induced palmar plantar erythrodysesthesia. J Clin Diagn Res 2014;8:HC01-3. [PMID: 25478366 DOI: 10.7860/JCDR/2014/9133.4975] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
38 Miller KK, Gorcey L, McLellan BN. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol. 2014;71:787-794. [PMID: 24795111 DOI: 10.1016/j.jaad.2014.03.019] [Cited by in Crossref: 104] [Cited by in F6Publishing: 111] [Article Influence: 13.0] [Reference Citation Analysis]
39 Gurumurthi R, Nimmagadda RB, Mohan S. Docetaxel-induced Hand and Foot Syndrome in a Patient with Metastatic Breast Carcinoma. Indian J Dermatol 2013;58:380-2. [PMID: 24082184 DOI: 10.4103/0019-5154.117309] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
40 Loganayagam A, Arenas Hernandez M, Corrigan A, Fairbanks L, Lewis CM, Harper P, Maisey N, Ross P, Sanderson JD, Marinaki AM. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. Br J Cancer 2013;108:2505-15. [PMID: 23736036 DOI: 10.1038/bjc.2013.262] [Cited by in Crossref: 108] [Cited by in F6Publishing: 114] [Article Influence: 12.0] [Reference Citation Analysis]
41 Orsucci D, Pizzanelli C, Alì G, Calabrese R, Ricci G, Lenzi P, Petrozzi L, Moretti P, Siciliano G. Nerve, muscle and heart acute toxicity following oxaliplatin and capecitabine treatment. Neuromuscular Disorders 2012;22:767-70. [DOI: 10.1016/j.nmd.2012.04.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
42 Fabbrocini G, Cameli N, Romano MC, Mariano M, Panariello L, Bianca D, Monfrecola G. Chemotherapy and skin reactions. J Exp Clin Cancer Res 2012;31:50. [PMID: 22640460 DOI: 10.1186/1756-9966-31-50] [Cited by in Crossref: 30] [Cited by in F6Publishing: 38] [Article Influence: 3.0] [Reference Citation Analysis]
43 Swofford HJ, Schenck RA. Capecitabine-Induced Hand and Foot Syndrome and the Reproducibility of Friction Skin. Academic Forensic Pathology 2011;1:365-371. [DOI: 10.23907/2011.051] [Reference Citation Analysis]
44 Ma Y, Tang L, Wang HX, Xu YC, Ma Y, Zhang FC. Capecitabine for the treatment for advanced gastric cancer: efficacy, safety and ethnicity. J Clin Pharm Ther. 2012;37:266-275. [PMID: 21950464 DOI: 10.1111/j.1365-2710.2011.01289.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
45 Stintzing S, Fischer von Weikersthal L, Vehling-Kaiser U, Stauch M, Hass HG, Dietzfelbinger H, Oruzio D, Klein S, Zellmann K, Decker T. Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial. Br J Cancer. 2011;105:206-211. [PMID: 21750558 DOI: 10.1038/bjc.2011.227] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
46 Almeida da Cruz L, Hoff PM, Ferrari CL, Riechelmann RS. Unilateral hand-foot syndrome: does it take sides? Case report and literature review. Clin Colorectal Cancer 2012;11:82-4. [PMID: 21764392 DOI: 10.1016/j.clcc.2011.05.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
47 Saif MW. Capecitabine and hand–foot syndrome. Expert Opinion on Drug Safety 2010;10:159-69. [DOI: 10.1517/14740338.2011.546342] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 2.8] [Reference Citation Analysis]
48 Wolf SL, Qin R, Menon SP, Rowland KM Jr, Thomas S, Delaune R, Christian D, Pajon ER Jr, Satele DV, Berenberg JL, Loprinzi CL; North Central Cancer Treatment Group Study N05C5. Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. J Clin Oncol 2010;28:5182-7. [PMID: 21060036 DOI: 10.1200/JCO.2010.31.1431] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 3.8] [Reference Citation Analysis]
49 Miura K, Kinouchi M, Ishida K, Fujibuchi W, Naitoh T, Ogawa H, Ando T, Yazaki N, Watanabe K, Haneda S, Shibata C, Sasaki I. 5-fu metabolism in cancer and orally-administrable 5-fu drugs. Cancers (Basel). 2010;2:1717-1730. [PMID: 24281184 DOI: 10.3390/cancers2031717] [Cited by in Crossref: 116] [Cited by in F6Publishing: 120] [Article Influence: 9.7] [Reference Citation Analysis]
50 Milne O, Cutts B, McLean C, Gin D. Palifermin-induced acral erythrodysaesthesia variant in the treatment of acute myeloid leukaemia. Australas J Dermatol 2011;52:59-61. [PMID: 21332696 DOI: 10.1111/j.1440-0960.2010.00682.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
51 Kang Y, Lee SS, Yoon DH, Lee SY, Chun YJ, Kim MS, Ryu M, Chang H, Lee J, Kim TW. Pyridoxine Is Not Effective to Prevent Hand-Foot Syndrome Associated With Capecitabine Therapy: Results of a Randomized, Double-Blind, Placebo-Controlled Study. JCO 2010;28:3824-9. [DOI: 10.1200/jco.2010.29.1807] [Cited by in Crossref: 76] [Cited by in F6Publishing: 79] [Article Influence: 6.3] [Reference Citation Analysis]
52 Disel U, Gürkut O, Abali H, Kaleağasi H, Mertsoylu H, Ozyilkan O, Saif MW. Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine. Cutan Ocul Toxicol 2010;29:140-2. [PMID: 20298142 DOI: 10.3109/15569521003699585] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
53 Degen A, Alter M, Schenck F, Satzger I, Völker B, Kapp A, Gutzmer R. The hand-foot-syndrome associated with medical tumor therapy - classification and management. J Dtsch Dermatol Ges 2010;8:652-61. [PMID: 20482685 DOI: 10.1111/j.1610-0387.2010.07449.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 56] [Article Influence: 2.9] [Reference Citation Analysis]
54 Yoshimoto N, Yamashita T, Fujita T, Hayashi H, Tsunoda N, Kimura M, Tsuzuki N, Yamashita H, Toyama T, Kondo N, Iwata H. Impact of prophylactic pyridoxine on occurrence of hand–foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer. Breast Cancer 2010;17:298-302. [DOI: 10.1007/s12282-009-0171-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
55 Sivaramamoorthy C, Thientosapol ES, Tattersall MH. Hand-foot syndrome after treatment with docetaxel. Med J Aust 2009;191:40. [PMID: 19580538 DOI: 10.5694/j.1326-5377.2009.tb02675.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
56 Mignogna MD, Fortuna G, Falleti J, Leuci S. Capecitabine-induced stomatitis: a likely pathogenetic mechanism of oral lichenoid mucositis. Eur J Clin Pharmacol 2009;65:1057-9. [PMID: 19521695 DOI: 10.1007/s00228-009-0674-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
57 Aprile G, Mazzer M, Moroso S, Puglisi F. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer. Anticancer Drugs. 2009;20:217-229. [PMID: 19247178 DOI: 10.1097/cad.0b013e3283293fd4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 2.5] [Reference Citation Analysis]
58 Park SD, Lee KY, Park SJ, Lee S, Lee SM. Hand-foot Syndrome Following Capecitabine (Xeloda®) Monotherapy for Colorectal Cancer. J Korean Soc Coloproctol 2009;25:227. [DOI: 10.3393/jksc.2009.25.4.227] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
59 Hénin E, You B, Vancutsem E, Hoff P, Cassidy J, Twelves C, Zuideveld K, Sirzen F, Dartois C, Freyer G, Tod M, Girard P. A Dynamic Model of Hand-and-Foot Syndrome in Patients Receiving Capecitabine. Clin Pharmacol Ther 2008;85:418-25. [DOI: 10.1038/clpt.2008.220] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
60 Ritter JM. Research and Education. Br J Clin Pharmacol 2008;66:1-3. [DOI: 10.1111/j.1365-2125.2008.03228.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
61 [DOI: 10.1109/iros.2006.282051] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]